Literature DB >> 15049789

Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.

Stuart J Knechtle1.   

Abstract

Campath-1H is a humanized monoclonal antibody directed at CD52 expressed on lymphocytes and other cells of the immune system. It has been tested extensively in lymphoid malignancies, autoimmune diseases including rheumatoid arthritis, multiple sclerosis, and organ transplantation. Although its use in children has been limited to date, so far it appears to be well tolerated in children. Currently, studies are being implemented to further assess its safety and efficacy in pediatric organ transplantation. Immune cell depletion using Campath-1H appears to be particularly useful in organ transplantation in that lower doses of maintenance immunosuppressive drugs are needed. This feature is particularly attractive in children.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15049789     DOI： 10.1046/j.1399-3046.2003.00139.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN： 1397-3142


  9 in total

1.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Authors:  Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

Review 2.  Pediatric kidney transplantation: a historical review.

Authors:  Priya S Verghese
Journal:  Pediatr Res       Date:  2016-10-12       Impact factor: 3.756

3.  Immune profile of pediatric renal transplant recipients following alemtuzumab induction.

Authors:  Sacha A De Serres; Bechara G Mfarrej; Ciara N Magee; Fanny Benitez; Isa Ashoor; Mohamed H Sayegh; William E Harmon; Nader Najafian
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

4.  Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.

Authors:  H P Tan; D J Kaczorowski; A Basu; M Unruh; J McCauley; C Wu; J Donaldson; I Dvorchik; L Kayler; A Marcos; P Randhawa; C Smetanka; T E Starzl; R Shapiro
Journal:  Am J Transplant       Date:  2006-08-04       Impact factor: 8.086

5.  Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.

Authors:  Kristen M Williams; Danielle Dietzen; Abeer A Hassoun; Ilene Fennoy; Monica Bhatia
Journal:  Pediatr Blood Cancer       Date:  2014-06-17       Impact factor: 3.167

6.  Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.

Authors:  Irene K Kim; Jua Choi; Ashley A Vo; Alexis Kang; Mitasha Patel; Mieko Toyoda; James Mirocha; Elaine S Kamil; J Louis Cohen; Sabrina Louie; Odette Galera; Stanley C Jordan; Dechu P Puliyanda
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

7.  Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy.

Authors:  Demetrius Ellis; Ron Shapiro; Michael Moritz; Abhay Vats; Amit Basu; Henkie Tan; Liise Kayler; Janine Janosky; Thomas E Starzl
Journal:  Transplantation       Date:  2007-06-27       Impact factor: 4.939

8.  Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

Authors:  D R Mould; A Baumann; J Kuhlmann; M J Keating; S Weitman; P Hillmen; L R Brettman; S Reif; P L Bonate
Journal:  Br J Clin Pharmacol       Date:  2007-05-16       Impact factor: 4.335

9.  Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.

Authors:  Marieke van der Zwan; Carla C Baan; Teun van Gelder; Dennis A Hesselink
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.